Ondansetron Injection Rx
Generic Name and Formulations:
Ondansetron (as HCl dihydrate) 2mg/mL; IV or IM inj.
Various generic manufacturers
Indications for Ondansetron Injection:
Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Prevention of post-op nausea and vomiting.
Chemotherapy (vials must be diluted; see full labeling): >18yrs: Infuse over 15 mins. 0.15mg/kg (max 16mg/dose) IV every 4hrs for 3 doses beginning 30 mins before chemotherapy. Severe hepatic dysfunction: max 8mg/day. Post-op (do not dilute): Infuse in not less than 30 seconds, preferably over 2–5 mins: 4mg IV as single dose immediately before induction of anesthesia; or shortly post-op if nausea or vomiting occurs. Or, may use 4mg IM undiluted as a single injection.
Chemotherapy (vials must be diluted; see full labeling): Infuse over 15 mins. <6 months: see full labeling. 6 months–18yrs: 0.15mg/kg (max 16mg/dose) IV for 3 doses every 4hrs beginning 30 mins before chemotherapy. Post-op (do not dilute): Infuse in not less than 30 seconds, preferably over 2–5 mins: <1 month: see full labeling. 1 month–12yrs (<40kg): 0.1mg/kg. ≥40kg: 4mg. Give IV as single dose immediately before induction of anesthesia; or shortly post-op if nausea or vomiting occurs.
<4 months of age (monitor closely). Not a substitute for nasogastric suction in gastric or intestinal peristalsis. Congenital long QT syndrome: avoid. Electrolyte abnormalities, CHF, bradyarrhythmias, concomitant drugs that prolong QT: monitor ECG. May mask progressive ileus and/or gastric distention. GI obstruction risk: monitor for decreased bowel activity. Hepatic dysfunction. Pregnancy. Nursing mothers.
See Contraindications. Profound hypotension, loss of consciousness with apomorphine. Serotonin syndrome possible esp. with concomitant serotonergic drugs (eg, SSRIs, SNRIs, MAOIs, mirtazapine, fentanyl, lithium, tramadol, IV methylene blue). May antagonize tramadol.
Selective 5-HT3 receptor antagonist.
Diarrhea, headache, fever, constipation, fatigue, transient blindness; serotonin syndrome (discontinue if occurs); rare: angina, bronchospasm, anaphylaxis, seizures, ECG changes (including QT prolongation).
Tabs 4mg, 8mg—30; ODT 4mg, 8mg—30; Oral soln, vials—contact supplier
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|